{"id":34887,"date":"2026-03-27T17:57:02","date_gmt":"2026-03-27T12:27:02","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=34887"},"modified":"2026-03-26T17:58:17","modified_gmt":"2026-03-26T12:28:17","slug":"lynavoy-for-pbc","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/lynavoy-for-pbc","title":{"rendered":"GSK\u2019s LYNAVOY Enters PBC Treatment Space, Targeting High-Burden Pruritus Segment"},"content":{"rendered":"\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>LYNAVOY is an oral IBAT inhibitor approved to treat cholestatic pruritus in adults with PBC, making it the first medicine in the US specifically cleared for this indication.<\/em><\/li>\n\n\n\n<li><em>Up to 89% of people with PBC experience cholestatic pruritus, an internal, often unbearable itch that can disrupt sleep, aggravate fatigue, and severely diminish quality of life.<\/em><\/li>\n\n\n\n<li><em>Approval is underpinned by the phase III GLISTEN trial, where 238 PBC patients with moderate to severe itch achieved clinically meaningful itch reductions versus placebo on a 10\u2011point WI\u2011NRS scale, with significant improvements emerging as early as two weeks and sustained over 24 weeks.<\/em><\/li>\n<\/ul>\n\n\n\n<p>The FDA has approved <strong>GSK\u2019s LYNAVOY (linerixibat)<\/strong>, ushering in a first-in-class breakthrough for cholestatic pruritus in adults with primary biliary cholangitis (PBC). This milestone signals a major leap in hepatology, finally delivering a targeted, mechanism-driven solution for a burdensome symptom that has long lacked effective treatment options. <\/p>\n\n\n\n<p>Primary biliary cholangitis is a chronic, autoimmune cholestatic liver disease in which immune\u2011mediated destruction of the small intrahepatic bile ducts leads to progressive cholestasis, fibrosis, cirrhosis, and ultimately liver failure or transplantation if left untreated. PBC predominantly affects middle\u2011aged women and is typically suspected when cholestatic liver biochemistries are identified or when patients present with symptoms such as fatigue or pruritus. Pruritus in PBC, often described as an intense \u201cinternal itch\u201d, is one of the most debilitating manifestations of the disease, severely impairing sleep, daily functioning, mental health, and overall quality of life. Epidemiological data cited by GSK indicate that up to <strong>89%<\/strong> of <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-biliary-cholongitis-pbc-epidemiology-forecast\">individuals living with PBC<\/a> experience cholestatic pruritus at some point in their disease course, underscoring its near\u2011ubiquitous impact in this population. In the United States alone, PBC is estimated to affect more than 100,000 adults, suggesting a substantial subset of patients with clinically significant itch and a high unmet need for targeted symptom control.<\/p>\n\n\n\n<p>Historically, management of PBC has focused on disease\u2011modifying therapy with UDCA as first\u2011line PBC treatment and additional agents such as obeticholic acid for patients with an inadequate biochemical response, but no therapy was specifically approved in the US to treat cholestatic pruritus itself. Off\u2011label approaches, including <strong>bile acid sequestrants, rifampin, opioid antagonists, and antidepressants<\/strong>, have been used with variable efficacy and tolerability, leaving many patients undertreated or unable to tolerate existing options. The approval of a targeted IBAT inhibitor such as LYNAVOY therefore addresses a highly visible gap in the PBC treatment armamentarium.<\/p>\n\n\n\n<p><strong>LYNAVOY <\/strong>is the brand name for <strong>linerixibat<\/strong>, an orally administered small\u2011molecule <a href=\"https:\/\/www.delveinsight.com\/report-store\/ibat-inhibitor-market-forecast\">IBAT inhibitor<\/a>. By blocking the reuptake of bile acids from the terminal ileum back into the enterohepatic circulation, IBAT inhibitors reduce circulating bile acid levels and downstream mediators thought to drive cholestatic itch. This mechanism provides a rational, targeted approach to pruritus in cholestatic liver disease, distinct from traditional systemic antipruritic drugs.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"374\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/LYNAVOY-Development-Timeline-1024x374.webp\" alt=\"LYNAVOY-Development-Timeline\" class=\"wp-image-34892\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/LYNAVOY-Development-Timeline-1024x374.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/LYNAVOY-Development-Timeline-300x110.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/LYNAVOY-Development-Timeline-150x55.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/LYNAVOY-Development-Timeline-768x281.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/LYNAVOY-Development-Timeline-1536x562.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/LYNAVOY-Development-Timeline.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>According to the FDA\u2011approved prescribing information, LYNAVOY is indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis in adult patients. It is, therefore, not a disease\u2011modifying agent for PBC per se, but a symptom\u2011focused therapy intended to be used alongside standard PBC treatments such as UDCA, rather than as a replacement. GSK highlights LYNAVOY as its first liver medicine to reach approval from its pipeline, emphasising the company\u2019s broader strategy to expand into liver disease and rare disease portfolios.<\/p>\n\n\n\n<p>Regulatory recognition reflects the rarity and severity of the condition: linerixibat has been granted <strong>Orphan Drug Designation<\/strong> in the United States, European Union, and Japan for the treatment of cholestatic pruritus in patients with PBC, and has been awarded priority review status in China. These designations confer incentives such as market exclusivity and regulatory support that can materially enhance the product\u2019s commercial attractiveness.<\/p>\n\n\n\n<p>Beyond the US, regulatory submissions for linerixibat are under review in multiple jurisdictions, including the <strong>European Union, the United Kingdom, Canada, and China<\/strong>. In China, the therapy has been granted <strong>priority review<\/strong> for cholestatic pruritus in PBC, reflecting unmet need and the potential for accelerated access if efficacy and safety are confirmed.<\/p>\n\n\n\n<p>The FDA\u2019s decision is primarily supported by the <strong>GLISTEN Phase III trial<\/strong>, a global, randomised, placebo\u2011controlled study enrolling adults with PBC and moderate\u2011to\u2011severe cholestatic pruritus despite stable background therapy. Participants were randomised to receive oral linerixibat or placebo in addition to their existing <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-biliary-cholongitis-pbc-market\">PBC treatment<\/a>, with follow\u2011up over 24 weeks.<\/p>\n\n\n\n<p>GLISTEN met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in itch intensity compared with placebo, as measured by patient\u2011reported instruments. Importantly for patient quality of life, itch relief was described as rapid, with improvements evident as early as week 2, and sustained across the 24\u2011week treatment period. Key secondary endpoints, including reductions in itch\u2011related sleep interference, were also achieved, supporting the broader impact of treatment beyond itch scores alone.<\/p>\n\n\n\n<p>The safety profile observed in GLISTEN was consistent with the known class effects of IBAT inhibition, typically involving gastrointestinal events attributable to alterations in bile acid handling. No new major safety signals have been publicly highlighted in the approval communications; however, longer\u2011term data and post\u2011marketing experience will be important to fully characterise the risk\u2013benefit balance in clinical practice.<\/p>\n\n\n\n<p>Ahead of the US approval, GSK announced a global licensing agreement with Italian pharmaceutical company <strong>Alfasigma S.p.A.<\/strong>, granting Alfasigma exclusive worldwide rights to develop, manufacture, and commercialise linerixibat. Under the terms of the deal, GSK stands to receive up to <strong>USD 690 million<\/strong> in aggregate payments, structured as a <strong>USD 300 million<\/strong> upfront payment, a <strong>USD 100 million<\/strong> milestone tied to anticipated US approval by late March, additional regulatory milestones for approvals in Europe and the UK, and up to <strong>USD 270 million<\/strong> in sales\u2011based milestones.<\/p>\n\n\n\n<p>In addition to these milestone payments, GSK will receive tiered double\u2011digit royalties on global sales of LYNAVOY generated by Alfasigma, maintaining economic participation in the asset despite transferring operational control. The transaction remains subject to customary closing conditions and regulatory clearances, including review under the Hart\u2011Scott\u2011Rodino Act in the United States.<\/p>\n\n\n\n<p>Alfasigma is one of the leading pharmaceutical companies in Italy, with a long\u2011standing commercial presence in gastroenterology and liver disease across more than 100 countries, positioning it as a logical commercial partner for a PBC\u2011focused therapy. For Alfasigma, LYNAVOY adds a differentiated, first\u2011in\u2011class IBS\u2011targeting medicine to its hepatology portfolio, expanding its reach in rare liver conditions and potentially strengthening its global footprint beyond its traditional markets.<\/p>\n\n\n\n<p>Several <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-biliary-cholangitis-pbc-pipeline-insight\">emerging PBC therapies<\/a> targeting bile acid transport and nuclear receptors are progressing through late\u2011stage development, including other IBAT inhibitors such as <strong>volixibat <\/strong>and PPAR agonists like <strong>saroglitazar<\/strong>, which have reported positive Phase III results and may seek regulatory approval in the coming years.&nbsp;<\/p>\n\n\n\n<p><em>Sadaf Javed, Manager of Forecasting at DelveInsight, said that in this competitive but still underserved landscape, LYNAVOY differentiates itself by being the first therapy in the US with a specific label for cholestatic pruritus in PBC, rather than focusing primarily on biochemical disease markers.<\/em><\/p>\n\n\n\n<p>Given its symptomatic focus, LYNAVOY is likely to be used in combination with standard PBC therapies, offering an add\u2011on option for patients who remain highly symptomatic despite biochemically controlled disease. This positioning may mitigate direct head\u2011to\u2011head competition with disease\u2011modifying agents and instead create opportunities for complementary use, particularly in patients whose primary complaint is relentless itching.<\/p>\n\n\n\n<p>The approval of LYNAVOY also validates IBAT inhibition as a therapeutic strategy for cholestatic pruritus, which may catalyse further research into similar mechanisms for other cholestatic liver diseases, such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-sclerosing-cholangitis-market\">primary sclerosing cholangitis<\/a> or intrahepatic cholestasis of pregnancy, although such indications would require dedicated clinical evaluation. As additional data accrue from long\u2011term extension studies, real\u2011world evidence, and potential head\u2011to\u2011head or combination trials, the understanding of where LYNAVOY fits best within the broader PBC management algorithm will continue to sharpen.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-biliary-cholongitis-pbc-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Primary-Biliary-Cholangitis-Market-Assessment-1024x194.webp\" alt=\"Primary Biliary Cholangitis Market Assessment\" class=\"wp-image-34893\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Primary-Biliary-Cholangitis-Market-Assessment-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Primary-Biliary-Cholangitis-Market-Assessment-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Primary-Biliary-Cholangitis-Market-Assessment-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Primary-Biliary-Cholangitis-Market-Assessment-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Primary-Biliary-Cholangitis-Market-Assessment-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Primary-Biliary-Cholangitis-Market-Assessment.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Summary The FDA has approved GSK\u2019s LYNAVOY (linerixibat), ushering in a first-in-class breakthrough for cholestatic pruritus in adults with primary biliary cholangitis (PBC). This milestone signals a major leap in hepatology, finally delivering a targeted, mechanism-driven solution for a burdensome symptom that has long lacked effective treatment options. Primary biliary cholangitis is a chronic, autoimmune [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":34894,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22738,22935,22934,20348,20352,18507,20346,20350],"industry":[17225],"therapeutic_areas":[17239],"class_list":["post-34887","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-ibat-inhibitor","tag-linerixibat","tag-lynavoy","tag-pbc","tag-pbc-drugs","tag-primary-biliary-cholangitis","tag-primary-biliary-cholangitis-treatment","tag-primary-biliary-cholangitis-treatment-market","industry-pharmaceutical","therapeutic_areas-gastroenterology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GSK Steps into PBC Arena with LYNAVOY, Eyeing Pruritus Relief<\/title>\n<meta name=\"description\" content=\"FDA has approved GSK\u2019s LYNAVOY (linerixibat), ushering in a first-in-class breakthrough for cholestatic pruritus in adults with PBC.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/lynavoy-for-pbc\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Steps into PBC Arena with LYNAVOY, Eyeing Pruritus Relief\" \/>\n<meta property=\"og:description\" content=\"FDA has approved GSK\u2019s LYNAVOY (linerixibat), ushering in a first-in-class breakthrough for cholestatic pruritus in adults with PBC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/lynavoy-for-pbc\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-27T12:27:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/lynavoy-for-pbc.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Steps into PBC Arena with LYNAVOY, Eyeing Pruritus Relief","description":"FDA has approved GSK\u2019s LYNAVOY (linerixibat), ushering in a first-in-class breakthrough for cholestatic pruritus in adults with PBC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/lynavoy-for-pbc","og_locale":"en_US","og_type":"article","og_title":"GSK Steps into PBC Arena with LYNAVOY, Eyeing Pruritus Relief","og_description":"FDA has approved GSK\u2019s LYNAVOY (linerixibat), ushering in a first-in-class breakthrough for cholestatic pruritus in adults with PBC.","og_url":"https:\/\/www.delveinsight.com\/blog\/lynavoy-for-pbc","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-03-27T12:27:02+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/lynavoy-for-pbc.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/lynavoy-for-pbc","url":"https:\/\/www.delveinsight.com\/blog\/lynavoy-for-pbc","name":"GSK Steps into PBC Arena with LYNAVOY, Eyeing Pruritus Relief","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/lynavoy-for-pbc#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/lynavoy-for-pbc#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/lynavoy-for-pbc.webp","datePublished":"2026-03-27T12:27:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"FDA has approved GSK\u2019s LYNAVOY (linerixibat), ushering in a first-in-class breakthrough for cholestatic pruritus in adults with PBC.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/lynavoy-for-pbc"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/lynavoy-for-pbc#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/lynavoy-for-pbc.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/lynavoy-for-pbc.webp","width":466,"height":284,"caption":"lynavoy-for-pbc"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/lynavoy-for-pbc-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IBAT Inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">linerixibat<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">LYNAVOY<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PBC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PBC Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Primary Biliary Cholangitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Primary Biliary Cholangitis Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Primary Biliary Cholangitis Treatment Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">IBAT Inhibitor<\/span>","<span class=\"advgb-post-tax-term\">linerixibat<\/span>","<span class=\"advgb-post-tax-term\">LYNAVOY<\/span>","<span class=\"advgb-post-tax-term\">PBC<\/span>","<span class=\"advgb-post-tax-term\">PBC Drugs<\/span>","<span class=\"advgb-post-tax-term\">Primary Biliary Cholangitis<\/span>","<span class=\"advgb-post-tax-term\">Primary Biliary Cholangitis Treatment<\/span>","<span class=\"advgb-post-tax-term\">Primary Biliary Cholangitis Treatment Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 months ago","modified":"Updated 2 months ago"},"absolute_dates":{"created":"Posted on Mar 27, 2026","modified":"Updated on Mar 26, 2026"},"absolute_dates_time":{"created":"Posted on Mar 27, 2026 5:57 pm","modified":"Updated on Mar 26, 2026 5:58 pm"},"featured_img_caption":"lynavoy-for-pbc","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=34887"}],"version-history":[{"count":6,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34887\/revisions"}],"predecessor-version":[{"id":34897,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34887\/revisions\/34897"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/34894"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=34887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=34887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=34887"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=34887"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=34887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}